Back to Search
Start Over
INFLAMMATORY BOWEL DISEASE CARE IN BRAZIL: HOW IT IS PERFORMED, OBSTACLES AND DEMANDS FROM THE PHYSICIANS’ PERSPECTIVE
- Source :
- Arquivos de Gastroenterologia, Vol 57, Iss 4, Pp 416-427 (2020), Arquivos de Gastroenterologia v.57 n.4 2020, Arquivos de gastroenterologia, Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia, instacron:IBEPEGE
- Publication Year :
- 2020
- Publisher :
- Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia (IBEPEGE), 2020.
-
Abstract
- BACKGROUND: Inflammatory bowel diseases (IBD) are chronic inflammatory affections of recurrent nature whose incidence and prevalence rates have increased, including in Brazil. In long term, they are responsible for structural damage that impacts quality of life, morbidity and mortality of patients. OBJECTIVE: To describe the profile of physicians who treat IBD patients as well as the characteristics of IBD care, unmet demands and difficulties. METHODS: A questionnaire containing 17 items was prepared and sent to 286 physicians from 101 Brazilian cities across 21 states and the Federal District, selected from the register of the State Commission of the “Study Group of Inflammatory Bowel Disease of Brazil” (GEDIIB). RESULTS: The majority of the physicians who answered the questionnaire were gastroenterologists and colorectal surgeons. More than 60% had up to 20 years of experience in the specialty and 53.14% worked at three or more locations. Difficulties in accessing or releasing medicines were evident in this questionnaire, as was referrals to allied healthy professionals working in IBD-related fields. More than 75% of physicians reported difficulties in performing double-balloon enteroscopy and capsule endoscopy, and 67.8% reported difficulties in measuring calprotectin. With regard to the number of patients seen by each physician, it was shown that patients do not concentrate under the responsibility of few doctors. Infliximab and adalimumab were the most commonly used biological medicines and there was a higher prescription of 5-ASA derivatives for ulcerative colitis than for Crohn’s disease. Steroids were prescribed to a smaller proportion of patients in both diseases. The topics “biological therapy failure” and “new drugs” were reported as those with higher priority for discussion in medical congresses. In relation to possible differences among the country’s regions, physicians from the North region reported greater difficulty in accessing complementary exams while those from the Northeast region indicated greater difficulty in accessing or releasing medicines. CONCLUSION: The data obtained through this study demonstrate the profile of specialized medical care in IBD and are a useful tool for the implementation of government policies and for the Brazilian society as a whole.
- Subjects :
- 0301 basic medicine
Enteroscopy
medicine.medical_specialty
Specialty
Professional practice location
Disease
RC799-869
Inflammatory bowel diseases
Inflammatory bowel disease
03 medical and health sciences
0302 clinical medicine
Quality of life (healthcare)
Physicians
Humans
Medicine
Medical prescription
business.industry
Incidence (epidemiology)
Gastroenterology
Diseases of the digestive system. Gastroenterology
medicine.disease
Ulcerative colitis
Infliximab
030104 developmental biology
Family medicine
Quality of Life
Colitis, Ulcerative
030211 gastroenterology & hepatology
business
Surveys and questionnaires
Brazil
Subjects
Details
- Language :
- English
- ISSN :
- 16784219
- Volume :
- 57
- Issue :
- 4
- Database :
- OpenAIRE
- Journal :
- Arquivos de Gastroenterologia
- Accession number :
- edsair.doi.dedup.....1f02e2d1a77f69c5e4951e39b60c849e